Missions

NASDAQ: ADTX

Aditxt is a social innovation platform accelerating promising innovations with the potential to address some of our most pressing health challenges.

Aditxt actively evaluates strategic acquisitions that align with its immune health focus, enhance its technology pipeline, and/or provide revenue-generating opportunities.

These acquisitions are part of Aditxt’s broader strategy to expand its portfolio, enhance its technological capabilities, and drive long-term value creation. Updates on these initiatives will be provided as discussions progress.

Current Focus Areas (Subsidiaries)

Through Adimune™, developing a transformative approach to autoimmunity—focused on restoring immune tolerance rather than suppressing the immune system.

Via Pearsanta™, advancing early cancer detection through precision diagnostics — with plans to develop adductomics-based screening to advance towards pre-cancer detection.

Adivue

Through Adivue™, advancing innovative solutions for neurodegenerative and neuroinflammatory conditions.

Planned Expansion Areas (Proposed Acquisitions)

Through Evofem™, addressing critical unmet needs in reproductive and sexual health.

Aditxt Video Library (NASDAQ: ADTX)

Featured News

March 24, 2025 – PR Newswire

Evofem Reports Fourth Consecutive Year of Net Sales Growth

March 24, 2025 – Businesswire

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

March 6, 2025 – Businesswire

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.